Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Epistemonikos ID: d0deaf11574ece312f3d054e6b501ad6481ca820
First added on: May 13, 2024